文献速递心力衰竭与心肌病

心力衰竭药物治疗疗效的性别差异:随机试验荟萃分析

Sex differences in pharmacological treatment of heart failure: a meta-analysis of randomized trials.
PubMed 文献 · Eur Heart J · 2026-01-01

基于78项报告了按性别分层疗效的试验,女性与男性对心力衰竭药物治疗的主要终点疗效无显著差异。女性入组比例与总体疗效或性别间疗效差异均未见关联。

要点

  • 心力衰竭药物治疗的主要终点疗效在女性和男性之间无显著差异。
  • 试验中女性入组比例与药物治疗总体疗效及性别间疗效差异均无关联。
  • 改善心力衰竭试验的性别平衡仍具有社会与伦理意义。

核心结论

  • 心力衰竭药物治疗的疗效不存在性别差异,历史上女性在试验中的代表性不足不太可能掩盖重要的性别特异性差异。

研究设计与样本

  • 纳入标准为评估心力衰竭药物治疗对比安慰剂或常规治疗的随机对照试验,样本量至少100例,主要结局为临床事件。

临床怎么用

  • 现有证据支持心力衰竭药物治疗在女性和男性中采用相同的疗效预期,无需因性别调整用药方案。

局限性

  • 仅78项试验报告了性别分层的疗效数据,其余试验未提供相关信息。
  • 女性在心力衰竭试验中的代表性仍然不足,可能影响其他非疗效维度的外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Women remain underrepresented in heart failure (HF) trials, raising concerns about potential undetected sex-specific differences in treatment efficacy. This study assesses sex differences in the primary efficacy endpoint of HF treatments and examines whether the proportion of women enrolled in a trial influences (variations in) treatment effect estimates. METHODS: A systematic search was conducted up to 21 March 2025, including randomized controlled trials (RCTs) (≥100 patients) evaluating pharmacological HF treatments vs. placebo or usual care, with clinical events as the primary outcome. Sex differences in the primary outcome were assessed using a random-effects meta-analysis of the reported relative effect measures (REM) and pooled estimates. For key clinical outcomes, meta-regression analyses were performed to examine the association between the proportion of women enrolled and sex differences in REMs, as well as the overall REMs without separating sex. RESULTS: Of 5749 screened publications, 139 RCTs met inclusion criteria, with 292 027 patients (28.1% women). Based on 78 RCTs that reported sex-stratified treatment effects, pooled analysis showed no difference in treatment efficacy between women and men (delta ln[REM] 0.00; 95% confidence interval (CI) -0.04 to 0.03; P = .85; I2 = 4.1%). Meta-regression found no association between the proportion of women and sex differences in REM (78 RCTs, P = .25), overall efficacy (139 RCTs, P = .24), or other clinical outcomes. CONCLUSIONS: These findings suggest that pharmacological efficacy in HF does not differ by sex and that historical female underrepresentation in trials is unlikely to have masked important sex differences. Nonetheless, improving sex balance in HF trials remains essential for societal and ethical reasons.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. van der Bijl, Scholte, van Oortmerssen, et al. Sex differences in pharmacological treatment of heart failure: a meta-analysis of randomized trials. Eur Heart J. 2026. PMID: 42048254. doi:10.1093/eurheartj/ehag311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。